Skip to main content

Advertisement

SpringerLink
Log in

Chemotherapy in metastatic renal cell cancer

  • Topic Paper
  • Published:
World Journal of Urology Aims and scope Submit manuscript

Abstract

Currently, there is no standard treatment for patients with advanced renal cell carcinoma (RCC) who do not respond to or progress after transient remission to first-line immunotherapy. At the end of the 1990s, no single chemotherapeutic drug, alone or in combination with interleukin-2 (IL-2) or interferon-alfa (IFN), had shown activity beyond the one expected by immunotherapy alone. New drugs on the market such as the pyrimidine analog gemcitabine or taxane-based chemotherapeutics may show promising tumor activity in combination with targeted therapy, but this has to be substantiated in upcoming trials. There is a great need to develop effective systemic therapy for advanced MRCC and to evaluate the efficacy of new drugs in clinical trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Motzer RJ, Russo P (2000) Systemic therapy for renal cell carcinoma. J Urol 163:408–417

    CAS  PubMed  Google Scholar 

  2. Mickisch G, Bier,H, Bergler W, et al. (1999) P-170 glycoprotein, glutathione and associated enzymes in relation to chemoresistance of primary human renal cell carcinomas. Urol Int 45:170–176

    Google Scholar 

  3. Juliano RL, Ling V (1976) A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 455:152–162

    CAS  PubMed  Google Scholar 

  4. Mickisch GH (1994) Chemoresistance of renal cell carcinoma: 1986–1994. World J Urol 12:214–223

    Google Scholar 

  5. Ford JM, Yang JM, Hait WN (1996) P-glycoprotein-mediated multidrug resistance: experimental and clinical strategies for its reversal. Cancer Treat Res 87:3–38

    CAS  PubMed  Google Scholar 

  6. Anderson ME (1998) Glutathione: an overview of biosynthesis and modulation. Chem Biol Interact 111/112:1–14

    Google Scholar 

  7. Mickisch GH, Noordzij MA, Van der Gaast A et al. (1995) Dexverapamil to modulate vinblastine resistance in metastatic renal cell carcinoma. J Cancer Res Clin Oncol 121 [Suppl 3]:R11–16

  8. Braybrooke JP, Vallis KA, Houlbrook S et al. (2000) Evaluation of toremifene for reversal of multidrug resistance in renal cell cancer patients treated with vinblastine. Cancer Chemother Pharmacol 46:27–34

    CAS  PubMed  Google Scholar 

  9. Gnarra JR, Tory K, Weng Y et al. (1994) Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 7:85–90

    Google Scholar 

  10. Bindra RS, Vasselli JR, Stearman R et al. (2002) VHL-mediated hypoxia regulation of cyclin D1 in renal carcinoma cells. Cancer Res 62:3014–3019

    PubMed  Google Scholar 

  11. Huang LE, Gu J, Schau M et al. (1998) Regulation of hypoxia-inducible factor 1alpha is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci U S A 95:7987–7992

    CAS  PubMed  Google Scholar 

  12. Hockel M, Vaupel P (2001) Biological consequences of tumor hypoxia. Semin Oncol 28:36–41

    CAS  Google Scholar 

  13. Fossa SD, Kramar A, Droz JP (1994) Prognostic factors and survival in patients with metastatic renal cell carcinoma treated with chemotherapy or interferon-alpha. Eur J Cancer 30A:1310–1314

    CAS  PubMed  Google Scholar 

  14. Thiesse P, Ollivier L, Di Stefano-Louineau D et al. (1997) Response rate accuracy in oncology trials: reasons for interobserver variability. Groupe Francais d’Immunotherapie of the Federation Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol 15:3507–3514

    CAS  PubMed  Google Scholar 

  15. Erasmus JJ, Gladish GW, Broemeling L et al. (2003) Interobserver and intraobserver variability in measurement of non-small-cell carcinoma lung lesions: implications for assessment of tumor response. J Clin Oncol 21:2574–2582

    Google Scholar 

  16. Duffaud F, Therasse P (2000) New guidelines to evaluate the response to treatment in solid tumors (in French). Bull Cancer 87:881–886

    CAS  PubMed  Google Scholar 

  17. Therasse P (2002) Measuring the clinical response. What does it mean? Eur J Cancer 38:1817–1823

    CAS  PubMed  Google Scholar 

  18. Hrushesky WJ, Von Roemeling R, Lanning RM et al. (1990) Circadian-shaped infusions of floxuridine for progressive metastatic renal cell carcinoma. J Clin Oncol 8:1504–1513

    Google Scholar 

  19. Yagoda A, Abi-Rached B, Petrylak D (1995) Chemotherapy for advanced renal-cell carcinoma: 1983–1993. Semin Oncol 22:42–60

    CAS  Google Scholar 

  20. Fossa SD, Droz JP, Pavone-Macaluso MM et al. (1992) Vinblastine in metastatic renal cell carcinoma: EORTC phase II trial 30882. The EORTC Genitourinary Group. Eur J Cancer 28A:878–880

    CAS  PubMed  Google Scholar 

  21. Marcus SG, Choyke PL, Reiter R et al. (1993) Regression of metastatic renal cell carcinoma after cytoreductive nephrectomy. J Urol 150:463–466

    CAS  PubMed  Google Scholar 

  22. Ryan CW, Vogelzang NJ, Stadler WM (2002) A phase II trial of intravenous gemcitabine and 5-fluorouracil with subcutaneous interleukin-2 and interferon-alpha in patients with metastatic renal cell carcinoma. Cancer 94:2602–2609

    CAS  PubMed  Google Scholar 

  23. Stadler WM, Huo D, George C et al. (2003) Prognostic factors for survival with gemcitabine plus 5-fluorouracil based regimens for metastatic renal cancer. J Urol 170:1141–1145

    CAS  PubMed  Google Scholar 

  24. Bennouna J, Delva R, Gomez F et al. (2003) A phase II study with 5-fluorouracil, folinic acid and oxaliplatin (FOLFOX-4 regimen) in patients with metastatic renal cell carcinoma. Oncology 64:25–27

    CAS  PubMed  Google Scholar 

  25. Haas NB, Giantonio BJ, Litwin S et al. (2003) Vinblastine and estramustine phosphate in metastatic renal cell carcinoma: a phase II trial of the Fox Chase Network. Cancer 98:1837–1841

    CAS  PubMed  Google Scholar 

  26. Oevermann K, Buer J, Hoffmann R et al. (2000) Capecitabine in the treatment of metastatic renal cell carcinoma. Br J Cancer 83:583–587

    CAS  PubMed  Google Scholar 

  27. Fizazi K, Rolland F, Chevreau C et al. (2003) A phase II study of irinotecan in patients with advanced renal cell carcinoma. Cancer 98:61–65

    CAS  PubMed  Google Scholar 

  28. Stadler WM, Kuzel T, Roth B et al. (1997) Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol 15:3394–3398

    CAS  PubMed  Google Scholar 

  29. De Mulder PH, Weissbach L, Jakse G et al. (1996) Gemcitabine: a phase II study in patients with advanced renal cancer. Cancer Chemother Pharmacol 37:491–495

    PubMed  Google Scholar 

  30. Porta C, Zimatore M, Imarisio I, et al. (2004) Gemcitabine and oxaliplatin in the treatment of patients with immunotherapy-resistant advanced renal cell carcinoma: final results of a single-institution Phase II study. Cancer 100:2132–2138

    CAS  PubMed  Google Scholar 

  31. Rini BI, Vogelzang NJ, Dumas MC et al. (2000) Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer. J Clin Oncol 18:2419–2426

    Google Scholar 

  32. Escudier B, Chevreau C, Lasset C et al. (1999) Cytokines in metastatic renal cell carcinoma: is it useful to switch to interleukin-2 or interferon after failure of a first treatment? Groupe Francais d’Immunotherape. J Clin Oncol 17:2039–2043

    CAS  PubMed  Google Scholar 

  33. Bruntsch U, Heinrich B, Kaye SB et al. (1994) Docetaxel (Taxotere) in advanced renal cell cancer. A phase II trial of the EORTC Early Clinical Trials Group. Eur J Cancer 30A:1064–1067

    CAS  PubMed  Google Scholar 

  34. Park DK, Ryan CW, Dolan ME et al. (2002) A phase II trial of oral temozolomide in patients with metastatic renal cell cancer. Cancer Chemother Pharmacol 50:160–162

    CAS  PubMed  Google Scholar 

  35. Townsley CA, Chi K, Ernst DS et al. (2003) Phase II study of troxacitabine (BCH-4556) in patients with advanced and/or metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada-Clinical Trials Group, J Clin Oncol 21:1524–1529

    Google Scholar 

  36. Berg WJ, Schwartz L, Yu R et al. (2001) Phase II trial of irofulven (6-hydroxymethylacylfulvene) for patients with advanced renal cell carcinoma. Invest New Drugs 19:317–320

    Article  CAS  PubMed  Google Scholar 

  37. Yang JC, Sherry RM, Steinberg SM et al. (2003) Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 21:3127–3132

    Article  PubMed  Google Scholar 

  38. Atzpodien J, Kirchner H, Siebels M et al. (2004) Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a prospectively randomized trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). J Clin Oncol 22:1188–1194

    Article  CAS  PubMed  Google Scholar 

  39. Bleumer I, Oosterwijk E, De Mulder P et al. (2003) Immunotherapy for renal cell carcinoma. Eur Urol 44:65–75

    CAS  PubMed  Google Scholar 

  40. Fossa SD, Mickisch GH, De Mulder PH et al. (2004) Interferon-alpha-2a with or without 13-cis retinoic acid in patients with progressive, measurable metastatic renal cell carcinoma. Cancer 101:533–540

    CAS  PubMed  Google Scholar 

  41. Motzer RJ, Murphy BA, Bacik J et al. (2000) Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. J Clin Oncol 18:2972–2980

    Google Scholar 

  42. Sunkara U, Walczak JR, Summerson L et al. (2004) A phase II trial of temozolomide and IFN-alpha in patients with advanced renal cell carcinoma. J Interferon Cytokine Res 24:37–41

    Google Scholar 

  43. Bacoyiannis C, Dimopoulos MA, Kalofonos HP et al. (2002) Vinblastine and interferon-gamma combination with and without 13-cis retinoic acid for patients with advanced renal cell carcinoma. Results of two phase II clinical trials. Oncology 63:130–138

    CAS  PubMed  Google Scholar 

  44. Negrier S, Caty A, Lesimple T et al. (2000) Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil. Groupe Francais d’Immunotherapie, Federation Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol 18:4009–4015

    CAS  PubMed  Google Scholar 

  45. Neri B, Cini G, Doni L et al. (2002) Weekly gemcitabine plus Epirubicin as effective chemotherapy for advanced pancreatic cancer: a multicenter phase II study. Br J Cancer 87:497–501

    CAS  PubMed  Google Scholar 

  46. Vaishampayan U, Flaherty L, Du W et al. (2001) Phase II evaluation of paclitaxel, alpha-interferon, and cis-retinoic acid in advanced renal cell carcinoma. Cancer 92:519–523

    CAS  PubMed  Google Scholar 

  47. Schwartsmann G, Medina De Cunha F, Silveira LA et al. (1991) Phase II trial of vinblastine plus nifedipine (VN) in patients with advanced renal cell carcinoma (RCC). Brazilian Oncology Trials Group. Ann Oncol 2:443

    CAS  Google Scholar 

  48. Gershanovich MM, Moiseyenko VM, Vorobjev AV et al. (1997) High-dose toremifene in advanced renal-cell carcinoma. Cancer Chemother Pharmacol 39:547–551

    CAS  PubMed  Google Scholar 

  49. Liu JH, Yang MH, Fan FS et al. (2001) Tamoxifen and colchicine-modulated vinblastine followed by 5-fluorouracil in advanced renal cell carcinoma: a phase II study. Urology 57:650–654

    CAS  PubMed  Google Scholar 

  50. Amarto RJ, Perez C, Pagliaro L (2002) Irofulven, a novel inhibitor of DNA synthesis in metastatic renal cell cancer. Invest New Drugs 20:413–417

    PubMed  Google Scholar 

  51. Gez E, Rubinov R, Gaitani D et al. (2002) Interleukin-2, interferon-alpha, 5-fluorouracil, and vinblastine in the treatment of metastatic renal cell carcinoma: a prospective phase II study: the experience of Rambam and Lin Medical Centers 1996–2000. Cancer 95:1644-1649

    CAS  PubMed  Google Scholar 

  52. Chaouche M, Pasturaud AL, Kamioner D et al. (2000) Oxaliplatin, 5-fluorouracil, and folinic acid (Folfox) in patients with metastatic renal cell carcinoma: results of a pilot study. Am J Clin Oncol 23:288-289

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology and Radiotherapy, The Norwegian Radium University Hospital, Oslo, Norway

    Wolfgang Lilleby & Sophie D. Fosså

Authors
  1. Wolfgang Lilleby
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sophie D. Fosså
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wolfgang Lilleby.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lilleby, W., Fosså, S.D. Chemotherapy in metastatic renal cell cancer. World J Urol 23, 175–179 (2005). https://doi.org/10.1007/s00345-004-0469-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00345-004-0469-x

Keywords

Search

Navigation